Nasdaq · CIK 0001400118
SGMT Sagimet Biosciences Inc.
Insider trading from SEC Form 4. Last filing Nov 21, 2025. Close $8.93 on Oct 9, 2026, +96% from the 52-week low and -20% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
SGMTOct 9, 2026 · close 8.93
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Sagimet Biosciences Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | George Kemble Executive Chairman sell | $290k 37,688 shares | -32% | - | |
| 59Moderate | David Happel President & CEO sell | $598k 65,478 shares | -9% | - | |
| 38Weak | Eduardo Bruno Martins Chief Medical Officer sell | $76k 8,277 shares | -7% | - | |
| 40Moderate | Elizabeth Rozek General Counsel and CCO sell | $98k 10,780 shares | -6% | - |
Transactions
The last 18 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | George Kemble Executive Chairman | SOpen-market sale Series A Common Stock10b5-1 | -37,688 | $7.69 | $290k | 81,005 | Nov 21, 2025 |
| Nov 4, 2025 | Elizabeth Rozek Chief Legal & Admin. Officer | AGrant or award Series A Common Stock | +9,855 | $0.00 | $0 | 193,581 | Nov 6, 2025 |
| Nov 4, 2025 | Elizabeth Rozek Chief Legal & Admin. Officer | AGrant or award Stock Option (Right to Buy)derivative | +13,367 | $0.00 | $0 | 13,367 | Nov 6, 2025 |
| Jul 21, 2025 | David Happel President & CEO | SOpen-market sale Series A Common Stock | -65,478 | $9.13 | $598k | 689,722 | Jul 23, 2025 |
| Jul 21, 2025 | Eduardo Bruno Martins Chief Medical Officer | SOpen-market sale Series A Common Stock | -8,277 | $9.13 | $76k | 106,936 | Jul 23, 2025 |
| Jul 21, 2025 | Elizabeth Rozek General Counsel and CCO | SOpen-market sale Series A Common Stock | -10,780 | $9.13 | $98k | 183,726 | Jul 23, 2025 |
| Jun 9, 2025 | George Kemble Executive Chairman | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | Jun 10, 2025 |
| Jun 6, 2025 | Beth C Seidenberg director | AGrant or award Stock Option (Right to Buy)derivative | +28,522 | $0.00 | $0 | 28,522 | Jun 10, 2025 |
| Jun 9, 2025 | Timothy P Walbert director | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | Jun 10, 2025 |
| Jun 9, 2025 | Anne M. Phillips director | AGrant or award Stock Option (Right to Buy)derivative | +27,268 | $0.00 | $0 | 27,268 | Jun 10, 2025 |
| Jun 9, 2025 | Jennifer Jarrett director | AGrant or award Stock Option (Right to Buy)derivative | +27,268 | $0.00 | $0 | 27,268 | Jun 10, 2025 |
| Jun 9, 2025 | Paul W. Hoelscher director | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | Jun 10, 2025 |
| Jun 9, 2025 | Elizabeth A Grammer director | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | Jun 10, 2025 |
| Jun 9, 2025 | Beth C Seidenberg director | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | Jun 10, 2025 |
| Feb 6, 2025 | Thierry Chauche Chief Financial Officer | AGrant or award Series A Common Stock | +17,000 | $0.00 | $0 | 17,000 | Feb 7, 2025 |
| Feb 6, 2025 | David Happel President & CEO | AGrant or award Series A Common Stock | +116,000 | $0.00 | $0 | 755,200 | Feb 7, 2025 |
| Feb 6, 2025 | Thierry Chauche Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +69,000 | $0.00 | $0 | 69,000 | Feb 7, 2025 |
| Feb 6, 2025 | David Happel President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +472,000 | $0.00 | $0 | 472,000 | Feb 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Thierry ChaucheChief Financial Officer
- Elizabeth A Grammerofficer, director
- David HappelPresident & CEO
- Paul W. Hoelscherdirector
- Jennifer Jarrettcoo, officer, director, ceo, president
- George KembleExecutive Chairman
- Eduardo Bruno MartinsChief Medical Officer
- Anne M. Phillipsdirector
- Elizabeth RozekChief Legal & Admin. Officer
- Beth C Seidenbergdirector, owner
- Timothy P Walbertdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.